Abstract
BackgroundA number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients. However, the results have been conflicting. To address this controversy, we conducted an analysis using a meta-analysis and a TCGA dataset to estimate the value of Ki-67 expression in the prognosis of OS.MethodsA comprehensive search for relevant papers was conducted using NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane Library, and CNKI regardless of the publication year. The associations between Ki-67 expression and the clinical features and main prognostic outcomes of OS were measured. The TCGA dataset was also analyzed. The pooled odds ratio (OR) and its 95% confidential intervals (CIs) were utilized for statistical analysis.ResultsOverall, a total of 12 studies with 500 cases were included, and the results indicated that the expression of Ki-67 was significantly associated with Enneking stage (OR = 6.88, 95% CI: 2.92–16.22, p < 0.05), distant metastasis (OR = 3.04, 95% CI: 1.51–6.12, p < 0.05) and overall survival (OR = 8.82, 95% CI: 4.68–16.65, p < 0.05) in OS patients. Additionally, we observed no significant heterogeneity among all retrieved studies. Associations between Ki-67 expression and overall survival and disease-free survival of sarcoma were confirmed using the TCGA and Kaplan-Meier plotter datasets.ConclusionThe present study strongly suggests that positive Ki-67 expression was associated with Enneking stage, distant metastasis, and overall survival of OS, and it may be used as a potential biomarker to predict prognosis and guide clinical therapy for OS.
Highlights
A number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients
The results indicated that Ki-67 was significantly upregulated in many cancers including sarcoma (SARC), stomach adenocarcinoma (STAD), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), colon adenocarcinoma (COAD) and liver hepatocellular carcinoma (LIHC) (Fig. 4a)
The results identified Ki-67 as a predictive marker for reduced 5-year overall survival (OR = 8.82, 95% 95% confidence interval (CI): 4.68–16.65, p < 0.05) in patients with OS
Summary
A number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients. To address this controversy, we conducted an analysis using a meta-analysis and a TCGA dataset to estimate the value of Ki-67 expression in the prognosis of OS. Many factors are responsible for prognosis, including demographics, sensitivity to chemotherapy and tumor size, site, and stage [4, 5]. Many prognostic biomarkers of osteosarcoma have been reported; for example, LRRC15 can be used as a prognostic. The indicators for prognosis were mainly about location, tumor size, recurrence rate, clinical stage and distant metastasis. To measure these indicator was not precise and efficient. It was really essential to identify a more representative biomarker for providing an effective prognosis for OS [4, 5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
